GW announces US launch of cannabinoid medicine for seizures

GW Pharmaceuticals, along with its US subsidiary Greenwich Biosciences, has launched EPIDIOLEX (cannabidiol) oral solution CV in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older